Obtenga las últimas noticias sobre las acciones de Metsera con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de MTSR

Últimas noticias sobre

METSERA INC

Metsera

Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Biotech

Large Cap

News

Health Care

Movers

Trading Ideas

General

MTSR

Metsera recibe oferta de Novo Nordisk valorada en 77,75$ por acción. Pfizer rechaza la propuesta y las acciones de Metsera suben más del 21%.

Metsera recibe oferta de Novo Nordisk y sus acciones suben mientras Pfizer responde

Metsera Inc

Press Releases

Metsera Receives Unsolicited Proposal from Novo Nordisk

Halper Sadeh LLC Encourages GES, MTSR, TGNA, CYBR Shareholders to Contact the Firm to Discuss Their Rights

Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition

Metsera Issues Statement in Response to Litigation

Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"

/C O R R E C T I O N -- Metsera, Inc./

$HAREHOLDER ALERT: The M&A Class Action Firm Encourages $hareholders to Act Before the Vote- CYBR, TGNA, MTSR, and GES

Halper Sadeh LLC Encourages TGNA, MTSR, CYBR Shareholders to Contact the Firm to Discuss Their Rights

Metsera Issues Statement in Response to Litigation Ruling

CYBR

TGNA

Abivax

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

Caris Life Sciences

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Merus

Nuvalent

Vaxcyte

PTC Therapeutics

Avidity Biosciences

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Rhythm Pharmaceuticals, Inc. - Common Stock

Comments

Metsera Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL